Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials
Open Access
- 16 November 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 3768